Tygh Capital Management Inc. lifted its holdings in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 30.3% during the 4th quarter, Holdings Channel reports. The firm owned 52,062 shares of the biotechnology company’s stock after acquiring an additional 12,105 shares during the period. BIO-TECHNE accounts for about 1.6% of Tygh Capital Management Inc.’s investment portfolio, making the stock its 23rd largest holding. Tygh Capital Management Inc.’s holdings in BIO-TECHNE were worth $7,534,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Advisors Asset Management Inc. increased its position in BIO-TECHNE by 41,650.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 7,515 shares of the biotechnology company’s stock valued at $1,112,000 after purchasing an additional 7,497 shares during the period. United Services Automobile Association increased its position in BIO-TECHNE by 11.4% during the 2nd quarter. United Services Automobile Association now owns 7,589 shares of the biotechnology company’s stock valued at $1,123,000 after purchasing an additional 778 shares during the period. Nisa Investment Advisors LLC increased its position in BIO-TECHNE by 10.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 19,050 shares of the biotechnology company’s stock valued at $3,888,000 after purchasing an additional 1,800 shares during the period. Argus Investors Counsel Inc. purchased a new position in BIO-TECHNE during the 3rd quarter valued at $426,000. Finally, BB&T Corp purchased a new position in BIO-TECHNE during the 3rd quarter valued at $234,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

TECH has been the topic of a number of research analyst reports. Stephens raised shares of BIO-TECHNE from an “equal weight” rating to an “overweight” rating and set a $180.00 price objective on the stock in a research report on Monday, January 14th. Goldman Sachs Group initiated coverage on shares of BIO-TECHNE in a report on Wednesday, October 17th. They set a “neutral” rating and a $190.00 target price on the stock. BidaskClub cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a report on Thursday, October 18th. Zacks Investment Research upgraded shares of BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Wednesday, November 28th. Finally, Craig Hallum cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating and dropped their target price for the company from $215.00 to $154.00 in a report on Wednesday, October 31st. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $188.13.

Shares of TECH stock traded up $1.69 during mid-day trading on Tuesday, reaching $185.49. 2,892 shares of the company’s stock traded hands, compared to its average volume of 273,043. BIO-TECHNE Corp has a 12 month low of $132.75 and a 12 month high of $206.04. The stock has a market cap of $6.94 billion, a PE ratio of 45.52, a price-to-earnings-growth ratio of 4.15 and a beta of 1.18. The company has a current ratio of 4.35, a quick ratio of 3.31 and a debt-to-equity ratio of 0.49.

BIO-TECHNE (NASDAQ:TECH) last announced its earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 EPS for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.08. BIO-TECHNE had a net margin of 14.02% and a return on equity of 13.90%. The firm had revenue of $174.50 million for the quarter, compared to analysts’ expectations of $171.39 million. During the same quarter in the previous year, the business posted $1.02 EPS. The company’s quarterly revenue was up 13.2% on a year-over-year basis. On average, sell-side analysts forecast that BIO-TECHNE Corp will post 3.68 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 15th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Thursday, February 14th. BIO-TECHNE’s dividend payout ratio (DPR) is presently 31.45%.

ILLEGAL ACTIVITY WARNING: “Tygh Capital Management Inc. Has $7.53 Million Stake in BIO-TECHNE Corp (TECH)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/02/12/tygh-capital-management-inc-has-7-53-million-stake-in-bio-techne-corp-tech.html.

About BIO-TECHNE

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.